Showing 1811-1820 of 5643 results for "".
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-
- Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscopehttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/Norlase announced the FDA 510(k) clearance and CE Mark for Norlase LYNX, which the company describes as the world’s first and only pattern scanning laser indirect ophthalmoscope. Commercially available now, the LYNX is battery-powered and provides surgeons the abili
- Dry Eye Institute Launches 'DEI On Demand' and Kicks Off Inaugural Road Eventhttps://modernod.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/The Dry Eye Institute (DEI), an educational program for optometrists and ophthalmologists specializing in advanced dry eye care, has announced that for the first time, the institute’s curriculum is now available online through 'DEI On Demand.' DEI also announced that
- ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901; DSMB Approval to Advance Dose Escalation in Phase 1b RP Trialhttps://modernod.com/news/vigeneron-announces-fda-rare-pediatric-disease-designation-for-vg901-dsmb-approval-to-advance-dose-escalation-in-phase-1b-rp-trial/2482601/ViGeneron announced two important milestones for its novel gene therapy candidate VG901 to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The FDA granted Rare Pediatric Disease Designation (RPD
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in Chinahttps://modernod.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/Nicox announced that its Denali phase 3 trial evaluating the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension is now fully enrolled in China and screening has been closed. Completion of recruitment of patients in the
- FDA Clears Novoxel's Tixel for the Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/Isreal-based Novoxel announced the the FDA clearance of its Tixel device for application of localized heat and pressure for patients with evaporative dry eye due to meibomian gland dysfunction (MGD). The Tixel systems use proprietary Thermo-Mechanical Actio
- Novaliq and Laboratoires Théa Announce EU Approval for Vevizye for Dry Eye Diseasehttps://modernod.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate to severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Nova
- Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidatehttps://modernod.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophth